Proton pump inhibitors often are prescribed in combination with clopidogrel to decrease risk of gastrointestinal bleeding after acute coronary syndrome. Clopidogrel is a prodrug that has to be metabolized in the liver to generate the active metabolite. Both medications are metabolized largely by the CYP2C19 enzyme; therefore, concerns exist that a drug-drug interaction during concomitant treatm...

The interindividual variability of Proton Pump Inhibitor (PPI) therapy results from the phenotype associated with cytochrome P450 2C19 (CYP2C19) gene, namely CYP2C19*17 allele. Our aim was to characterize patients’ genetic undergoing PPI therapy. A sample 33 oral mucosa cells Portuguese pharmacy patients collected, followed by genotyping. allelic frequencies CYP2C19*1 (-806C) and (-806T) were 7...

BACKGROUND Polymorphisms in CYP2C19 are related to the metabolic oxidation of drugs to varying degrees. The CYP3A4*18, CYP3A5*3, and MDR1-3435 variant alleles are very important, particularly in tacrolimus metabolism in organ transplant rejection. AIM The aim of this study is o explore possible interactions among different CYP2C19 genotypes, namely, between homozygous extensive metabolizers (...

This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 20...

DESCRIPTION Helicobacter pylori infection of the gastrointestinal (GI) tract is treated with a combination of antibiotics and proton-pump inhibitors (PPI). Genetic factors may influence the success of H pylori treatment through effects on PPI metabolism. Individuals with polymorphisms in the CYP2C19 gene metabolize PPIs more rapidly than normal and may have a reduced therapeutic effect. Therefo...

Abstract Background This research aims to study the association of genetic polymorphism in genes coding for CYP2C9 and CYP2C19 phenytoin-induced dose-related toxicity assess if presence allele CYP2C9*3 plays a role idiosyncratic adverse effects. Current observational case control included 142 patients with drug reactions (ADRs) 100 controls. All these underwent genotyping determine type [CYP2C9...

Over the last decade, dual antiplatelet therapy has been polymorphism and bleeding outcomes in their analysis. shown to be of significant benefit for secondary prevention in millions of patients with acute coronary syndromes (ACS), in those undergoing percutaneous coronary interventions (PCI), and in those with atrial fibrillation unable to take warfarin. Much like any other therapeutic agent, ...

OBJECTIVE Platelet α2A-adrenergic receptors (ARs) mediate platelet aggregation in response to sympathetic stimulation. The 6.3-kb variant of α2A-AR gene is associated with increased epinephrine-induced platelet aggregation in healthy volunteers. The cytochrome P450 2C19*2 (CYP2C19*2) loss-of-function allele influences P2Y12-mediated platelet inhibition and hence the rate of major adverse cardio...

To assess the effects of intestinal cytochrome P450 2C19 on the interaction between tacrolimus and proton pump inhibitors, we examined the concentration/dose ratio [(ng/ml)/(mg/day)] of tacrolimus coadministered with omeprazole (20 mg) or lansoprazole (30 mg) to 89 adult living-donor liver transplant patients on postoperative days 22 to 28, considering the CYP2C19 genotypes of the native intest...